Bioavailability & Bioequivalence ppt

Bioavailability & Bioequivalence ppt, Objectives, Improving bioavailability, Assessment of bioavailability, Urinary excretion studies, Blood serum studies, in vitro drug dissolution testing, need for dissolution testing, in vitro drug dissolution testing models, Bioequivalence, Therapeutic equivalence, Types of bioequivalence studies, Pharmacokinetic studies, Methods to enhance dissolution rate.

1. BIOAVAILABILITY
AND
BIOEQUIVALENCE
Presented by:
Aditya Sharma
M.S. (Pharm)
Pharmaceutical Analysis
NIPER Guwahati

2. BIOAVAILABILITY
•Itisrelativeamountofdrugfromanadministereddosageform
whichentersthesystemiccirculationandrateatwhichthedrug
appearsinthesystemiccirculation.
•Theextentandrateatwhichitsactivemoietyisdeliveredfrom
pharmaceuticalformandbecomesavailableinthesystemic
circulation

3. Why do we care about BIOAVAILABILITY?
The “true dose” is not the drug swallowed; BUT is the drug available
to exert its effect.
Bioavailable fraction (F), refers to the fraction of administered dose
that enters the systemic circulation.
F = Bioavailable dose
Administered dose

4. Objectives of bioavailability studies
•Developmentofnewformulation.
•Determinationofinfluenceofexcipients,patientrelatedfactorsand
possibleinteractionwithotherdrugsontheefficiencyofabsorption.
•Controlofqualityofadrugproductduringtheearlystagesofmarketingin
ordertodeterminetheinfluenceofprocessingfactors,storage,stabilityon
drugabsorption.
•Primarystagesofthedevelopmentofasuitabledosageformforanew
drugentity.
•Toformulateanewdosageformoftheexistingdrugmoleculewhichcan
beusedduringemergency

5. REASONS OF POOR BIOAVAILABILITY
Poor aqueous
solubility
Inappropriate
partition
coefficient
First-pass
metabolism
Degradation
due to low pH
in stomach
Degradation
due to
chemical
reactions
taking place in
gastrointestinal
tract
Interaction
with food
Route of
administration

6. HOW TO IMPROVE BIOAVAILABILITY
•Byincreasingtheaqueousdrugsolubilityie.bymakingsaltsofthedrug.
•Bymaintainingthedrugspartitioncoefficient.
•Bysynthesizingprodrugs.
•EntericcoatingofdrugspreventsitsdegradationinstomachpH.
•Iffoodispresentinstomachthanitmaydecreasesthedrugsabsorptionandforthis
themedicationcanbepreferredbeforemealorafter2-3hours.
•I/Vgivendrughashighestbioavailability.

8. RELATIVE BIOAVAILABILITY
•Compares the bioavailability of a formulation (A) of a certain drug
when compared with another formulation (B) of the same drug,
usually an established standard
•Fr=AUCA
AUCB
•Eg. Comparison of amoxicillin cap and suspension

9. ASSESSMENT OF BIOAVAILABILITY
➢Pharmacokinetics method –This method is more practical and discriminative.
Pharmacokinetic methods are of two types.
a)Determination of whole blood, plasma or serum concentration
b)Urinary excretion method
➢Pharmacodynamic methods:
•Acute Pharmacologic Response Method : When bioavailability measurement by pharmacokinetic
method is difficult, an acute pharmacologic effect such as effect on pupil diameter, heart rate or BP can
be useful as an index of drug bioavailability.
•Bioavailability can then be determined by construction of pharmacological effect-time curve as well as
dose response graphs
•Disadvantage: It tends to be complex, expensive, time-consuming and require a sensitive and
quantitative measure of the desired response.
•Therapeutic Response Method: Clinical response of the drug for which it is intended to be used is
measured.
•E.g.: heart rate, body temperature, blood sugar levels, and for anti-inflammatory drugs, reduction in
inflammation is determined.
•Drawbacks: quantification of observed response is too improper to allow for reasonable assessment of
relative bioavailability between two dosage forms of the same drug.

10. A) The blood (or serum or plasma) concentration-time curve -
•Widely used and based on assumption that Pharmacokinetic profile reflects the
therapeutic effectiveness of a drug. Plasma Level-Time Studies:
•Most common type of human bioavailability studies.
•Based on the assumption that there is a direct relationship between the concentration
of drug in blood or plasma and the concentration of drug at the site of action.
•Following the administration of a single dose of a medication, blood samples are
drawn at specific time intervals and analyzed for drug content.
•If the drugs are given to the volunteers through iv dose, the blood samples should be
withdraw after 5min. And the frequency of sampling should be 15min.

11. •A profile is constructed showing the concentration of drug in
blood at the specific times the samples were taken.
•Bioavailability (the rate and extent of drug absorption) is
generally assessed by the determination of following three
parameters. They are..
•Cmax (Peak plasma concentration)
•tmax(time of peak)
•Area under curve

13. AUC: The AUC is proportional to the total amount of drug reaching
the systemic circulation, and thus characterizes the extent of
absorption.
Cmax: Gives indication whether drug is sufficiently absorbed
systemically to provide a therapeutic response.
Tmax:The Tmax reflects the rate of drug absorption, and decreases as
the absorption rate increases.
MEC: The minimum plasma concentration of the drug required to
achieve a given pharmacological or therapeutic response
MSC: plasma concentration of the drug beyond which adverse effects
are likely to happen

15. Urinary Excretion Studies
•Urinaryexcretionofunchangeddrugisdirectlyproportionaltoplasma
concentrationofdrug.
•Thus,evenifadrugisexcretedtosomeextent(atleast10to20%)inthe
bioavailabilitycanbedetermined.eg:Thiazidediuretics,Sulphonamides.
•Methodisusefulwhenthereislackofsufficientlysensitiveanalyticaltechnique
tomeasuredrugconcentration.
•Noninvasivemethod,sobetterpatientcompliance.
•Thistechniqueofstudyingbioavailabilityismostusefulforthosedrugsthatare
notextensivelymetabolizedpriortourinaryelimination.

17. The three major parameters examined in urinary excretion data are
as follow:
1.(dXu/dt)max : maximum urinary excretion rate, gives the rate of
appearance of drug in the urine is proportional to its concentration
in systemic circulation. Its value increases as the rate of and/or
extent of absorption increases.
2. (tu)max : time for maximum excretion rate, is analogous to the of
plasma level data, its value decreases as the absorption rate
increases.
3. Xu : cumulative amount of drug excreted in the urine is related to
the AUC of plasma level data and increases as the extent of
absorption increases

20. INVITRO DRUG DISSOLUTION TESTING

21. DISSOLUTION
•Itisaprocessbywhichdrugreleasedfromsoliddosageformand
immediatelygoesintomolecularsolution.
•ItisaRateDeterminingStep.
•Ifthedrugishydrophilicwithhighaqueoussolubilitythendissolutionis
rapidandratedeterminingstepintheabsorptionofsuchdrugsisrate
ofpermeationthroughthebiomembrane.
•AbsorptionofsuchdrugsissaidtobepermeationratelimitedorTran’s
membraneratelimited.

23. NEED FOR DISSOLUTION TESTING:
Evaluation of bioavailability.
Batch to batch drug release uniformity.
Development of more efficacious and therapeutically ACTIVE dosage
forms.
Ensures quality and stability of the product.

24. IN-VITRO DISSOLUTION TESTING MODELS
Non-Sink methods
1)NATURAL CONVECTION NON SINK METHODS:
a) Klein solvmeter method
b) Nelson hanging pellet method
c) Levy static disk method
2) FORCED CONVECTION NON SINK METHODS:
a) Tumbling method
b) Levy or Beaker method
c) Rotating disk method
d) Particle size method
e) USP Rotating basket apparatus
f) USP Paddle apparatus

25. Sink Methods
3) FORCED CONVECTION SINK DEVICES:
a) Wurster pollis adsorption method
b) Partition method
c) Dialysis method s
d) Rotating disk apparatus
4) CONTINOUS FLOW/FLOW THROUGH METHODS:
a) Pernarowski method
b) Langenbucher method
c) Baun and Walker
d) Tingstad and Reigelman
e) Modified column apparatus
f) Takenaka method

26. NATURAL CONVECTION NONSINK METHOD
Klein Solvmeter method:
•Carrier device surrounded by flat and is immersed in
dissolution medium
•When dosage form is placed in the boat the bar moves and as
dosage form dissolves it moves upwards
•Amount of dosage form dissolved is revealed from the difference
in height of bar movement

27. Levy static Disk method:
•Acrylic holder containing dosage form is inserted into a known
volume of medium through rubber stopper.
•The vial is inverted and placed in incubator at 37 C .At specific
time intervals the vial is removed from incubator and samples are
analyzed.
•Disadvantages :-effect of conc. On dissolution medium is ignored
and the surface area of dosage form while dissolving is assumed
constant which is not impractical.

28. FORCED CONVECTION NON SINK METHODS
a. Tumbling Method:
•The Drug/ Dosage form with the dissolution medium is placed in test tube that is in turn clamped to
the revolving drum which is rotated at the speed of 6-12rpm in water bath at 37 C
•The test tubes are removed and the medium is assayed at regular time points for the dissolved drug
amount
b. Beaker method
•Reported by Levy and Hayes(1960).
•Dissolution medium, 250ml of 0.1N HCl at 37°C placed in a 400ml beaker.
•Agitation by three blade polyethylene stirrer,5cm diameter and rotates at 60 rpm.
•Stirrer immersed to a depth of 2.7 cm in medium and in the center.
•Tablets are placed in a beaker and test was carried out.
•Samples are removed and assayed for the content

29. c. Rotating disk method:
•Developed by late Einonelson and described by Levy and Sahli.
•In this method ,the drug is compressed in a non-disintegrating disc
without excipients.
•The disc is mounted in a holder so that only one face of the disc is
exposed to the dissolution medium.
•The holder and disc are immersed in medium and held in a fixed
position as in static disc method and rotated at a given speed in
rotating disc method.
•Samples are collected at predetermined times.
•Surface area of the drug through which dissolution occurs is kept
constant –intrinsic dissolution rate.

30. d. USP ROTATING BASKET:
•DESIGN:
Vessel: -Made of borosilicate glass.
-Semi hemispherical bottom
-Capacity 1000ml
Shaft : -Stainless steel 316
-Rotates smoothly without significance wobble(100 rpm)
-Speed regulator
Water bath:-Maintained at 37±0.5ºC
USE: Tablets, capsules, delayed release suppositories, floating dosage
forms.

31. Forced Convection Sink Devices:
A. Wurster-Polli Adsorption Method:
In this method the dissolved drug is adsorbed by charcoal or
bentonite. Care should be taken regarding the adsorbent, adsorbent
should not alter the viscosity of the medium
B. Partition Method:
In this device organic phase is employed to remove the dissolved
drug such that the drug would partition between the lipophilic and
hydrophilic phases. selection of organic phase plays a critical role.

32. Flow Through Devices
a) CONTINUOUS FLOW APPARATUS BY PERNAROWSKI
•It consists of 10 mesh stainless steel basket stirrer assembly with
an adjustable stirrer.
•the chamber is 3 necked flask of 33 mm and the rest two of 20
mm diameter.
•1L of medium is employed within the flask. the dissolution
characteristics are dependent upon the amount of medium
pumped through the dissolution chamber

33. B. LANGENBUCHER COLUMN
•This device is according to the dissolution basic design .
•The screen is constructed such that the medium flows equally
through the entire cross section in a laminar pattern.
•This is again closed by a secondary screen, filter which prevents
the undissolved drug from being eluted.

35. C. CONTINUOUS FLOW APPARATUS BY TAKENAKA
•Thereleaseofdrugismeasuredwiththeaidofinvitrosimulatordevice
consistingofflowtypedissolutioncontainer.
•Thedosageformisplacedinthebasketrotatingat94rpmwith300mlof
medium.
•Thenthemediumisremovedbycollectingreservoirusingperistalticpump.
•AliquotsarewithdrawnusingsyringeandthenfilteredusingWhatmanfilter
paperandthesamevolumeis
•Replacedimmediatelywithfreshmedium.

37. Bioequivalence
•Bioequivalence :-It is a relative term which denotes that the drug
substance in two or more identical dosage forms, reaches the
systemic circulation at the same relative rate and to the same
relative extent i.e. their plasma concentration-time profiles will be
identical without significant statistical differences
•When a generic drug is claimed bioequivalent to a Reference drug,
it is assumed that they are therapeutically equivalent

38. Therapeutic equivalence
Two products are therapeutically equivalent if
•pharmaceutically equivalent
•their effects, with respect to both efficacy and safety, will be
essentially the same as derived from appropriate studies including
bioequivalence studies, pharmacodynamic studies, clinical studies,
in vitro studies

40. TYPES OF BIOEQUIVALENCE STUDIES
•Bioequivalence can be demonstrated either –
In vivo, or
In vitro.

41. In vivo bioequivalence studies are conducted in the usual manner as
discussed for bioavailability studies, i.e. the pharmacokinetic and the
pharmacodynamic methods.
1. Pharmacokinetic Methods
a)Plasma level-time studies
b)Urinary Excretion studies
2. Pharmacodynamic Methods
a)Acute pharmacological response
b)Therapeutic response

42. In vitro studies, i.e. dissolution studies can be used in lieu of
in vivo bioequivalence under certain circumstances, called
as biowaivers(exemptions)
1. The drug product differs only in strength of the active substance It contains,
provided all the following conditions hold –
•Pharmacokinetics are linear.
•The qualitative composition is the same.
•The ratio between active substance and the excipients is the same, or (in the case of
small strengths) the ratio between the excipients is the same.
•Both products are produced by the same manufacturer at the same production site.
•A bioavailability or bioequivalence study has been performed with a original
product.
•Under the same test conditions, the in vitro dissolution rate is the same

43. Pharmacokinetic
Studies

51. METHODS TO ENHANCE THE DISSOLUTION
RATE
1.Increaseintheeffectivesurfaceareaofthedrug.
2.Particlesizereduction
3.Incorporationofsurfaceactiveagentsinformulation.EGnon-ionicsurfactantslike
polysorbatesarewidelyused.
4.Solute-Solventcomplexationreactions.
5.Polymorphism.E.g.Riboflavinexistin1,2,3formsbutform3is20timesmore
solublethan1
6.Molecularencapsulationwithcyclodextrinsorcomplexationwith
cyclodextrins.
7.Prodrugapproach.
8.Saltformationofdrug.

52. References
•ChowSC,LiuJP.DesignandAnalysisofBioavailabilityandBioequivalence
Studies.3.ChapmanHall/CRCPress,Taylor&Francis;NewYork,NewYork,USA:
2008.
•BalantLP.Isthereaneedformoreprecisedefinitionsofbioavailability?European
JournalofClinicalPharmacology.1991;40:123–126.
•ChenML,LeskoL,WilliamsRL.Measuresofexposureversusmeasuresofrate
andextentofabsorption.ClinicalPharmacokinetics.2001;40:565–572.
•ChowSC,ShaoJ.Analternativeapproachfortheassessmentofbioequivalence
betweentwoformulationsofadrug.BiometricalJournal.1990;32:969–976
•http://www.slideworld.com/slideshow.aspx/Bioavailability-and-
Bioequivalenceppt-2810356